A detailed history of Black Rock Inc. transactions in Ocuphire Pharma, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 106,935 shares of OCUP stock, worth $113,351. This represents 0.0% of its overall portfolio holdings.

Number of Shares
106,935
Previous 96,714 10.57%
Holding current value
$113,351
Previous $194,000 15.98%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.51 - $2.23 $15,433 - $22,792
10,221 Added 10.57%
106,935 $163,000
Q1 2024

May 10, 2024

BUY
$1.89 - $3.27 $4,522 - $7,825
2,393 Added 2.54%
96,714 $194,000
Q4 2023

Feb 13, 2024

BUY
$2.59 - $3.64 $2,683 - $3,771
1,036 Added 1.11%
94,321 $283,000
Q3 2023

Nov 13, 2023

BUY
$3.35 - $4.33 $126,918 - $164,046
37,886 Added 68.39%
93,285 $312,000
Q2 2023

Aug 11, 2023

BUY
$3.63 - $6.38 $11,608 - $20,403
3,198 Added 6.13%
55,399 $240,000
Q1 2023

May 12, 2023

SELL
$3.01 - $3.85 $58,698 - $75,078
-19,501 Reduced 27.2%
52,201 $195,000
Q4 2022

Feb 13, 2023

BUY
$2.04 - $3.53 $10,169 - $17,597
4,985 Added 7.47%
71,702 $253,000
Q3 2022

Nov 14, 2022

SELL
$1.82 - $2.79 $8,102 - $12,421
-4,452 Reduced 6.26%
66,717 $135,000
Q2 2022

Aug 12, 2022

BUY
$1.8 - $3.25 $66,425 - $119,934
36,903 Added 107.7%
71,169 $136,000
Q1 2022

May 12, 2022

SELL
$2.75 - $4.39 $3,687 - $5,886
-1,341 Reduced 3.77%
34,266 $112,000
Q4 2021

Feb 10, 2022

BUY
$3.4 - $5.19 $5,759 - $8,791
1,694 Added 5.0%
35,607 $133,000
Q3 2021

Nov 09, 2021

SELL
$3.84 - $5.38 $1,973 - $2,765
-514 Reduced 1.49%
33,913 $175,000
Q2 2021

Aug 11, 2021

BUY
$4.24 - $6.57 $145,970 - $226,185
34,427 New
34,427 $181,000

Others Institutions Holding OCUP

About Ocuphire Pharma, Inc.


  • Ticker OCUP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,579,800
  • Market Cap $21.8M
  • Description
  • Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...
More about OCUP
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.